ArticleTranslational oncology2025
Knockdown of LRP11-AS1 inhibits papillary thyroid tumor growth by modulating miR-615-3p/AKT2 axis.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with papillary thyroid cancer (PTC) who experience local recurrence and distant metastases have a poor clinical prognosis and low survival rate. In this study, the expression of LRP11-AS1 was evaluated in both tissue samples from patients with papillary thyroid cancer and in PTC cell lines. We observed significant overexpression of LRP11-AS1 in both PTC tissues and PTC cell lines and inhibitory effects of LRP11-AS1 knockdown on the growth and migration of PTC cells. Mechanistically, knockdown of LRP11-AS1 led to upregulation of miR-615-3p, overexpression of miR-615-3p decreased the expression of both LRP11-AS1 and AKT2. The dual-luciferase reporter assay confirmed the inhibitory effect of miR-615-3p on the expression of LRP11-AS1 and AKT2. Knockdown of LRP11-AS1 inhibited in vivo growth of PTC tumor in nude mice model. LRP11-AS1 exhibited potential oncogenic effects in PTC by regulating the miR-615-3p/AKT2 axis, suggesting that LRP11-AS1 could serve as a potential diagnostic biomarker and therapeutic target in PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.